March 18, 2025 04:15 AM EDTUpdated 06:15 AM

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe

Kyle LaHucik

Senior Reporter

European life sciences investor Sofinnova Partners disclosed a €165 million acceleration fund on Tuesday to back early-stage science in Italy, France, the United Kingdom and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

CRISPR company Arbor raises $73.9M to test therapy in clinical trials

AstraZeneca taps Alteogen in deal worth more than $1.3B to make subcutaneous cancer drugs

AstraZeneca reports Phase 3 success for rare disease drug at heart of Amolyt deal

FDA staff return to White Oak campus en masse after Trump administration push

Trump’s HHS defends Biden-era stance on 340B rebate models

AstraZeneca to buy cell therapy startup for $425M upfront

Sofinno­va Part­ners lands €165M, backed by big phar­ma, to build ear­ly-stage biotechs in Eu­rope

Senior Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe